Hospira, Inc. (HSP), a provider of injectable drugs and infusion technologies, Monday announced the submission of a Biologics License Application or BLA to the U.S. Food and Drug Administration for Retacrit. The drug is a biomilar of Amgen's Epogen and Janssen's Procrit. Earlier in mid December, the company has submitted biosimilar application under 351(K).
Biosimilars are biologic drugs that are highly similar to a reference biopharmaceutical product and demonstrate no clinically meaningful differences in terms of the safety, purity and potency of the product. Biosimilars offer high-quality, lower-cost alternatives to reference biologics.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.